Allergic bronchopulmonary aspergillosis
MONDO:0015243Allergic bronchopulmonary aspergillosis (ABPA) is a rare immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus, clinically manifesting with poorly controlled asthma and recurrent pulmonary infiltrates.
Also known as: ABPA, Hinson-Pepys disease, allergic aspergillosis, allergic bronchopulmonary aspergillosis, familial, allergic bronchopulmonary mycosis, aspergillosis, allergic bronchopulmonary
24 clinical trials for this condition and its sub-types, 15 tagged with Allergic bronchopulmonary aspergillosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Allergic bronchopulmonary aspergillosis
-
Malt worker's lung 0 trials
-
Can an injected biologic cut steroid Flare-Ups in a Tough-to-Treat asthma complication?
Disease control Not yet recruitingResearchers are studying depemokimab, an injected biologic drug, in adults aged 18 to 75 who have allergic bronchopulmonary aspergillosis (ABPA) along with severe eosinophilic asthma. The study tracks how many asthma attacks need systemic steroids and whether participants' qualit…
Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a single injection tame severe asthma in fungal allergy?
Disease control Not yet recruitingThis study is testing whether tezepelumab, an injectable medication, can help people with severe asthma caused by allergic bronchopulmonary aspergillosis (ABPA), a condition where the immune system overreacts to certain fungi. The trial will enroll 10 adults aged 18 to 75 who hav…
Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Massive asthma study tests phone apps and simple home fixes
Disease control Not yet recruitingThis large study aims to create a digital screening and management system for adults with asthma and allergies. Nearly 10,000 participants will use a smartphone platform to track symptoms and receive guidance on three non-drug strategies: avoiding allergens (like dust mites), inc…
Sponsor: Beijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New allergy shot for teens enters early safety testing
Symptom relief Not yet recruitingThis early-stage study tests a new injection called JYB1904 in 12 teenagers aged 12-17 with allergies like hay fever, asthma, or food allergies. The main goal is to see if the drug is safe and how the body processes it. Participants will be closely monitored for side effects and …
Phase 1 • Sponsor: Jemincare • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC